Ngai P K, Walsh M P
Department of Medical Biochemistry, Faculty of Medicine, University of Calgary, Alberta, Canada.
Biochem J. 1987 Jun 1;244(2):417-25. doi: 10.1042/bj2440417.
Caldesmon is a major calmodulin- and actin-binding protein of smooth muscle which interacts with calmodulin in a Ca2+-dependent manner or with actin in a Ca2+-independent manner. Isolated caldesmon is capable of inhibiting the actin-activated Mg2+-ATPase of smooth-muscle myosin, suggesting a possible physiological role for caldesmon in regulating the contractile state of smooth-muscle. Caldesmon can be phosphorylated in vitro by a co-purifying Ca2+/calmodulin-dependent protein kinase and dephosphorylated by a protein phosphatase, both of which are present in smooth muscle. We investigated further the phosphorylation of caldesmon and the effects which phosphorylation has on the functional properties of the protein. The kinetics of caldesmon phosphorylation were similar whether the caldesmon substrate was free or bound to actin, actin/tropomyosin or thin filaments. Caldesmon containing endogenous kinase activity was rapidly phosphorylated (to approx. 1 mol of Pi/mol of caldesmon in 5 min) when reconstituted with actin, myosin, tropomyosin, calmodulin and myosin light-chain kinase in the presence of Ca2+ and MgATP2-. Under conditions in which unphosphorylated caldesmon showed substantial inhibition of the actin-activated myosin Mg2+-ATPase, no inhibition was observed with phosphorylated caldesmon. This was the case whether caldesmon was phosphorylated before addition to the actomyosin Mg2+-ATPase system, or phosphorylation was allowed to take place during the ATPase reaction. Binding studies revealed maximal binding of 1 mol of unphosphorylated caldesmon/9.5 mol of actin and 1 mol of phosphorylated caldesmon/11.7 mol of actin. All the bound phosphorylated caldesmon could be released by Ca2+/calmodulin, with half-maximal release at 0.11 microM-Ca2+, whereas only 62% of the bound unphosphorylated caldesmon could be removed, with half-maximal release at 0.16 microM-Ca2+. However, under conditions in which inhibition of actomyosin Mg2+-ATPase activity by non-phosphorylated but not by phosphorylated caldesmon was observed, both forms of caldesmon would remain bound to the thin filament. These observations suggest a possible mechanism whereby caldesmon phosphorylation may prevent its inhibitory action on the actomyosin Mg2+-ATPase.
钙调蛋白是平滑肌中一种主要的钙调素和肌动蛋白结合蛋白,它以钙依赖的方式与钙调素相互作用,或以钙非依赖的方式与肌动蛋白相互作用。分离出的钙调蛋白能够抑制平滑肌肌球蛋白的肌动蛋白激活的镁 - 三磷酸腺苷酶,这表明钙调蛋白在调节平滑肌收缩状态方面可能具有生理作用。钙调蛋白在体外可被共纯化的钙/钙调素依赖性蛋白激酶磷酸化,并被一种蛋白磷酸酶去磷酸化,这两种酶都存在于平滑肌中。我们进一步研究了钙调蛋白的磷酸化以及磷酸化对该蛋白功能特性的影响。无论钙调蛋白底物是游离的还是与肌动蛋白、肌动蛋白/原肌球蛋白或细肌丝结合,钙调蛋白磷酸化的动力学都是相似的。当在钙离子和镁 - 三磷酸腺苷存在的情况下,将含有内源性激酶活性的钙调蛋白与肌动蛋白、肌球蛋白、原肌球蛋白、钙调素和肌球蛋白轻链激酶重组时,它会迅速被磷酸化(在5分钟内达到约1摩尔磷酸根/摩尔钙调蛋白)。在未磷酸化的钙调蛋白对肌动蛋白激活的肌球蛋白镁 - 三磷酸腺苷酶有显著抑制作用的条件下,磷酸化的钙调蛋白未观察到抑制作用。无论是在将钙调蛋白添加到肌动球蛋白镁 - 三磷酸腺苷酶系统之前进行磷酸化,还是在三磷酸腺苷酶反应过程中进行磷酸化,都是如此。结合研究表明,未磷酸化的钙调蛋白与肌动蛋白的最大结合量为1摩尔/9.5摩尔肌动蛋白,磷酸化的钙调蛋白与肌动蛋白的最大结合量为1摩尔/11.7摩尔肌动蛋白。所有结合的磷酸化钙调蛋白都可被钙/钙调素释放,在0.11微摩尔/升钙离子时达到半数最大释放,而只有62%的结合未磷酸化钙调蛋白可被去除,在0.16微摩尔/升钙离子时达到半数最大释放。然而,在观察到未磷酸化而非磷酸化的钙调蛋白抑制肌动球蛋白镁 - 三磷酸腺苷酶活性的条件下,两种形式的钙调蛋白都会保持与细肌丝结合。这些观察结果提示了一种可能的机制,即钙调蛋白磷酸化可能会阻止其对肌动球蛋白镁 - 三磷酸腺苷酶的抑制作用。